A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

A Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-115 in the Treatment of Rosacea

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00667173

Enrollment

140

Registered

2008-04-25

Start date

2007-11-30

Completion date

2008-07-31

Last updated

2012-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.

Interventions

DRUGIDP-115

Topical application for 12 weeks

DRUGVehicle

Topical application for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presence of facial rosacea * Presence of inflammatory lesions

Exclusion criteria

* Dermatological conditions of the face that could interfere with clinical evaluations * Known history of photosensitivity disorders (such as lupus erythematosus or polymorphous light eruption) * Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Design outcomes

Primary

Measure	Time frame
Change from baseline in the number of inflammatory lesions	12 weeks
Improvement from baseline in global severity	12 weeks

Secondary

Measure	Time frame
Change from baseline in erythema	12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026